We are studying whether a combination of Fianlimab and Cemiplimab is more effective than Cemiplimab alone for adults with advanced non-small cell lung cancer. This trial focuses on patients whose tumors express PD-L1 at high levels.
Health conditions and diseases that the clinical trial is designed to study and treat.
Advanced Non-Small Cell Lung Cancer (NSCLC) is a type of lung cancer that has spread beyond the lungs to other parts of the body. It is the most common form of lung cancer and can cause symptoms such as persistent cough, chest pain, shortness of breath, and weight loss.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
